"A great step in treating cervical cancer": Patient and provider perceptions about cervical cancer therapeutic vaccines.
Ashley Whitmer, Lindsay N Fuzzell, Sylea Lowery and 7 others
PMID 38878586WHAT IT FOUND
Patients and providers were open to therapeutic cervical cancer vaccines, seeing them as less invasive options with fewer side effects.
However, acceptance depended on clear information about how the vaccines work, costs, and eligibility. Mistrust and logistical barriers remained significant concerns.
Key findings
01Most patients indicated they would be willing to try a therapeutic vaccine for cervical cancer, while a minority wanted to learn more first.
02Patients valued the potential for a therapeutic vaccine to avoid invasive procedures and long-term side effects associated with current treatments.
03Both patients and providers cited limited understanding of how therapeutic vaccines work as a primary barrier to acceptance.
STILL TO COME
How it was doneWhat they foundWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
Small sample size (28 participants) limits the breadth of perspectives. Only two patients had pre-cancerous lesions, so findings are heavily weighted toward those with cancer diagnoses. Providers were recruited only from the principal investigator's professional network, which may not reflect broader clinical views. Participants received only cursory information about therapeutic vaccines during the interview, which may have influenced their perceptions of efficacy and safety.
The easy way to misread this
Do not interpret this openness as evidence that therapeutic vaccines are effective or approved. No vaccine has received FDA approval for this use, and the study only reports perceptions of a hypothetical treatment.